Healthy
Conditions
Keywords
Healthy, Ultracet extended release (ER), Tramadol hydrochloride, Acetaminophen, Bioequivalence
Brief summary
The purpose of this study is to evaluate the bioequivalence of a newly developed ULTRACET extended-release (ER) tablet of tramadol hydrochloride and acetaminophen, to the current marketed ULTRACET ER tablet, in healthy participants under fasted condition.
Interventions
DRUGTramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)
Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
DRUGTramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)
Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
Sponsors
Janssen Korea, Ltd., Korea
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Signed an informed consent document indicating they understand the purpose of and procedures required for the study and are willing to participate * Must agree to use an adequate contraception method as deemed appropriate by the investigator (e.g., vasectomy, double-barrier, partner using effective contraception) and to not donate sperm during the study and for 3 months after receiving the last dose of study drug * Body mass index (weight \[kg\]/height2 \[m\]2) between 18.5 and 30 kg/m2 (inclusive), and body weight not less than 50 kg * Blood pressure (after the participant is sitting for 5 minutes) between 90 and 140 mm Hg systolic, inclusive, and no higher than 90 mm Hg diastolic * A 12-lead electrocardiogram (ECG) consistent with normal cardiac function, including sinus rhythm, pulse rate between 45 and 90 bpm, QTc interval \<= 450 ms, QRS interval of \<110 ms, PR interval \<200 ms, and morphology consistent with healthy cardiac function
Exclusion criteria
* History of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic (blood) disease, coagulation disorders (including any abnormal bleeding), lipid abnormalities, significant lung disease (including bronchospastic respiratory disease), diabetes mellitus, kidney or liver insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results * Clinically significant abnormal values for hematology, clinical chemistry or urinalysis at screening or at admission to the study center as deemed appropriate by the investigator * Clinically significant abnormal physical examination, vital signs or 12-lead ECG at screening (or at admission to the study center) as deemed appropriate by the investigator * Use of any prescription or nonprescription medication (including vitamins and herbal supplements), except for oral contraceptives and hormonal replacement therapy within 14 days before the first dose of the study drug is scheduled * History of, or reason to believe a participant has a history of, drug or alcohol abuse within the past 5 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentrations of acetaminophen (Period 2) | Up to 48 hours following the administration of study drug on Day 1 of Period 2 |
| Plasma concentrations of racemic tramadol (Period 1) | Up to 48 hours following the administration of study drug on Day 1 of Period 1 |
| Plasma concentrations of acetaminophen (Period 1) | Up to 48 hours following the administration of study drug on Day 1 of Period 1 |
| Plasma concentrations of racemic tradamdol (Period 2) | Up to 48 hours following the administration of study drug on Day 1 of Period 2 |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events as a measure of safety and tolerability | Approximately 5 weeks |
Countries
South Korea
Outcome results
None listed